Investigators said the RAAS study filled in missing information on the value of dose modulations and infusion interval changes for patients with ankylosing spondylitis (AS) treated with CT-P13 (Remsima, Inflectra).
Investigators said dose adjustments and infusion interval changes have demonstrated potential to improve clinical outcomes in the 5-year RAAS (Rheumatoid Arthritis and Ankylosing Spondylitis) study of patients with ankylosing spondylitis (AS) treated with a biosimilar form of infliximab (CT-P13, Inflectra, Remsima).
CT-P13 is approved for use in 98 countries, and the generally approved maintenance regimen is 5 mg/kg infused every 6 to 8 weeks. Whereas variations on standard dosage and infusion intervals can be beneficial for patients, real-world data on such modulations for CT-P13 were lacking.
In this Republic of Korea retrospective study, the effect of changes in dosage and infusion for patients (18 years old) with AS (N = 337) were evaluated. The study included patients naive to infliximab treatment with CT-P13 (n = 219) and those who switched from the reference product (n = 118).
Investigators said 7.7%, 49.1%, and 54.3% of evaluable patients had dose, infusion interval, or combined treatment pattern changes, respectively. Disease activity improvements were greater for patients who underwent treatment pattern changes, although drug survival did not change significantly between patients with and without changes in treatment patterns.
“Findings suggest that adjusting the dose and/or infusion interval can improve clinical outcomes for CT-P13–treated patients with AS,” the authors wrote.
Prior Studies of Infliximab in AS
Prior studies have shown that lower-dose (3 mg/kg) infliximab treatment can be effective in AS; however, the same is not true across the board. Patients with psoriatic arthritis have not experienced significantly improved drug survival or treatment response at doses lower than 5 mg/kg, and patients with rheumatoid arthritis have seen improved clinical response with infliximab dose and infusion interval adjustments.
“In patients with AS, individualized dose/interval adjustments based on treatment response may be warranted to achieve clinical targets in some cases” and “lower-dose infliximab has been demonstrated to be well tolerated in patients with AS and is associated with significantly lower health care system costs,” the authors wrote.
In the RAAS analysis, 45.7% of evaluable patients did not have dose or infusion interval changes, and these were considered the control group. In this study, more CT-P13–naive patients (61.0%) had dose or interval changes than switched patients (42.6%).
Baseline dose groups were as follows: <4 mg/kg (n = 71), ≥ 4 to < 5 mg/kg (n = 117), and ≥ 5 mg/kg (n = 82). Whereas baseline demographics and disease characteristics were similar between these groups, patients in the < 4-mg/kg group had the lowest median Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores overall.
“Following initial decreases as naive patients initiated CT-P13, median BASDAI scores remained consistent over time,” the investigators said. “Drug survival did not differ significantly between baseline dose groups overall or for naive patients.”
In the infusion interval analysis, the investigators said although median baseline infusion intervals were slightly lower in the treatment-naive cohort (6-8 weeks) compared with overall and switched patients, mean infusion intervals increased slightly from year 1 to year 3 in all groups and decreased in year 4, most notably in the treatment-naive group.
“Switched patients had longer infusion intervals than naive patients throughout,” the investigators said.
Study Conclusions
The 5-year analysis was successful in elucidating treatment patterns with CT-P13 in patients with AS in routine clinical practice, they concluded.
Changes to infusion intervals were more common than dosage changes, and greater improvements in BASDAI scores were observed in the combined-changes vs combined-constant group, suggesting “that adjusting dose and/or infusion interval can improve clinical outcomes for patients with AS receiving CT-P13 treatment,” the authors said.
“Drug survival was comparable between baseline dose groups, with no adverse impact of lower baseline doses,” they wrote.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.